Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,864.00
Bid: 1,862.00
Ask: 1,870.00
Change: -22.00 (-1.17%)
Spread: 8.00 (0.43%)
Open: 1,814.00
High: 1,878.00
Low: 1,814.00
Prev. Close: 1,886.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition and strategic partnership

23 Feb 2017 07:00

RNS Number : 6110X
Genus PLC
23 February 2017
 

 

 

 

For immediate release 23 February 2017

Genus plc

('Genus' or the 'Group')

 

Acquisition and Strategic Partnership

Genus acquires Hermitage's genetic assets and enters into a strategic partnership

 

Genus, a leading global animal genetics company, and Hermitage, one of the longest established pig breeding companies in Europe, are pleased to announce that they have signed an agreement to enter into a strategic partnership covering the supply of porcine genetics in several markets.

 

PIC, Genus's porcine division, will acquire the genetic rights and intellectual property of Hermitage. Hermitage will also become a strategic supply chain and distribution partner for PIC. In addition, PIC will acquire certain Hermitage customer relationships in various geographies including Russia, the US and several European countries. The transaction is subject to a number of closing conditions which are expected to be fulfilled by the end of March 2017.

 

The partnership combines PIC's genetics expertise and quality, and Hermitage's supply chain network and operational excellence. This combination will strengthen PIC's ability to deliver genetic improvement in Europe and provide customers of both PIC and Hermitage with access to top-tier genetics and optimal technical and health services.

 

Hermitage was established in 1958 in Ireland and is one of the longest established porcine breeding and genetics companies in Europe. Over the years, Hermitage has grown into a multinational porcine breeding company serving pig producers in Europe and other international markets with high-health breeding stock. Hermitage's infrastructure includes nucleus farms and boar studs in Ireland and across Europe, as well as multiplication partners in key international territories.

 

Commenting on the transaction, Karim Bitar, Chief Executive of Genus, commented:

 

"The partnership with Hermitage is an ideal fit with our porcine strategy. It will provide Genus with the opportunity to accelerate genetic improvement by combining the PIC and Hermitage gene pools. In addition, Hermitage's strong supply chain and customer-service oriented team will strengthen our ability to serve pig producers efficiently and reliably."

 

Ned Nolan, owner of Hermitage, added:

 

"This is an exciting step for Hermitage, as we join forces with a global pioneer in our field. Our partnership with PIC will allow the continued use of the Hermitage gene pool to provide enhanced genetics to our global customer base. Hermitage shares PIC's values of pioneering genetic improvement for customers and we look forward to collaborating with PIC's team."

 

For further information, please contact:

 

Genus Tel: +44(0)1256 345970

Karim Bitar, Chief Executive

Stephen Wilson, Group Finance Director

Buchanan Tel: +44(0)207 466 5000

Charles Ryland /Vicky Hayns

 

This announcement is available on the Genus website www.genusplc.com

 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

 

Genus's worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

About Hermitage

Hermitage was established in 1958 by the Nolan Family. Pedigree Landrace and Large White lines were purchased internationally and developed and selected with the support of Irish Government Central Test Stations in the 60s, 70s and 80s. Over the last 30 years Hermitage Genetics has expanded its Landrace, Large White, Duroc, Pietrain and Maxgro lines, becoming a pig breeding company dedicated to efficient and profitable pig production worldwide. Hermitage top class production facilities support customers across Europe, North America and Asia.

 

Hermitage has developed a science-based breeding program that drives genetic progress focused on traits that are of economic importance to the pig producer. Hermitage now tests over 30,000 pigs per year for lean efficient growth and collects data from more than 22,000 pure-bred sows at the genetic nucleus level. This data is analysed by Hermitage's proprietary BreedDirect BLUP software program and offered by Hermitage to customers through an online data portal. Hermitage Group was advised on the transaction by Investec Corporate Finance in Dublin.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQOKBDDDBKBABB
Date   Source Headline
28th Jun 20215:00 pmRNSPIC AND SERGAL ENTER INTO STRATEGIC RELATIONSHIP
22nd Jun 20217:00 amRNSCapital Markets Event & PRRSv Programme Update
14th Jun 20213:01 pmRNSNotification of Major Holdings
7th Jun 202110:42 amRNSApplication For Additional Listing
4th Jun 20214:38 pmRNSNotification of Major Holdings
17th May 20211:23 pmRNSNotification of Major Holdings
13th May 202110:50 amRNSDirector/PDMR Shareholding
9th Apr 20214:10 pmRNSDirector/PDMR Shareholding
6th Apr 20216:00 pmRNSDirector/PDMR Shareholding
1st Apr 20215:49 pmRNSTotal Voting Rights
31st Mar 20212:59 pmRNSDirector/PDMR Shareholding
22nd Mar 20217:00 amRNSBoard Changes
19th Mar 202112:20 pmRNSDirector/PDMR Shareholding
9th Mar 20215:41 pmRNSNotification of Major Holdings
3rd Mar 20215:19 pmRNSDirector/PDMR Shareholding
26th Feb 202112:39 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSInterim Results
1st Feb 202111:08 amRNSBlock listing Interim Review
1st Feb 202111:08 amRNSTotal Voting Rights
18th Jan 20217:00 amRNSTrading Update
2nd Dec 20205:44 pmRNSDirector/PDMR Shareholding
25th Nov 20201:13 pmRNSResult of AGM
25th Nov 20207:00 amRNSAGM Trading Update - Strong Performance Continues
11th Nov 20201:03 pmRNSNOTIFICATION OF MAJOR HOLDINGS
16th Oct 20208:00 amRNSAnnual Report and Annual General Meeting
1st Oct 20203:45 pmRNSTotal Voting Rights
25th Sep 20206:14 pmRNSDirector/PDMR Shareholding
23rd Sep 20209:35 amRNSDirector/PDMR Shareholding
16th Sep 202012:16 pmRNSDirector/PDMR Shareholding
15th Sep 20205:52 pmRNSDirector/PDMR Shareholding
9th Sep 202012:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
8th Sep 20203:16 pmRNSApplication for Additional Listing
8th Sep 20207:00 amRNSPreliminary Results
1st Sep 20201:03 pmRNSTotal Voting Rights
3rd Aug 20204:15 pmRNSBlock listing Interim Review
1st Jul 202010:41 amRNSTotal Voting Rights
30th Jun 20203:45 pmRNSNOTIFICATION OF MAJOR HOLDINGS
29th Jun 20207:00 amRNSDirectorate Appointment
14th May 20206:23 pmRNSApplication for Block Listing
1st May 20203:04 pmRNSTotal Voting Rights
30th Apr 202010:24 amRNSCompliance with LR 9.2.6ER(1)
22nd Apr 20205:47 pmRNSDirector/PDMR Shareholding
21st Apr 202012:14 pmRNSNotification of Major Holdings
20th Apr 20209:28 amRNSDirector/PDMR Shareholding
8th Apr 20207:00 amRNSDirector/PDMR Shareholding
1st Apr 20205:52 pmRNSTotal Voting Rights
27th Feb 20207:00 amRNSInterim Results
26th Feb 202012:44 pmRNSNOTIFICATION OF MAJOR HOLDINGS
17th Feb 20205:27 pmRNSNotification of Major Holdings
7th Feb 20209:03 amRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.